Inotuzumab ozogamicin as chemotherapy-sparing salvage in a 67-year-old man with primary refractory B-cell acute lymphoblastic leukemia with high-risk genomic features

Inotuzumab ozogamicin as chemotherapy-sparing salvage in a 67-year-old man with primary refractory B-cell acute lymphoblastic leukemia with high-risk genomic features

Older adults with acute lymphoblastic leukemia (ALL) continue to have a poor prognosis, in part due to greater chemotherapy-related toxicities. We herein report a 67-year-old man with Philadelphia chromosome (Ph)-negative B-cell ALL, who exhibited refractoriness to 3 different regimens of induction...

Full description

Bibliographic Details
Main Authors: Xiaochuan Yang, Filiz Sen, Mark B. Geyer
Format: Article
Language:English
Published: Elsevier 2019-01-01
Series:Leukemia Research Reports
Online Access:http://www.sciencedirect.com/science/article/pii/S2213048919300494
id doaj-4f35040aada741558d1cbaab70411633
record_format Article
spelling doaj-4f35040aada741558d1cbaab704116332020-11-24T21:23:15ZengElsevierLeukemia Research Reports2213-04892019-01-0112Inotuzumab ozogamicin as chemotherapy-sparing salvage in a 67-year-old man with primary refractory B-cell acute lymphoblastic leukemia with high-risk genomic featuresXiaochuan Yang0Filiz Sen1Mark B. Geyer2Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, United States; Department of Medicine, Mount Sinai St Luke's and Roosevelt Hospital Center, New York, NY, United StatesDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, United StatesLeukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, United States; Cellular Therapeutics Center, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States; Corresponding author at: Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, United States.Older adults with acute lymphoblastic leukemia (ALL) continue to have a poor prognosis, in part due to greater chemotherapy-related toxicities. We herein report a 67-year-old man with Philadelphia chromosome (Ph)-negative B-cell ALL, who exhibited refractoriness to 3 different regimens of induction chemotherapy and experienced multiple complications including intracranial bleeding and respiratory failure, who achieved minimal residual disease (MRD)-negative complete response (CR) after a single cycle of inotuzumab ozogamicin (IO). His ALL was characterized by several high-risk mutations, which may have contributed to chemotherapy-refractory disease. Our case supports incorporating IO into front-line induction regimens for older adults with high-risk B-cell ALL. Keywords: Acute lymphoblastic leukemia, Inotuzumab ozogamicin, Older adults, Immunotherapyhttp://www.sciencedirect.com/science/article/pii/S2213048919300494
collection DOAJ
language English
format Article
sources DOAJ
author Xiaochuan Yang
Filiz Sen
Mark B. Geyer
spellingShingle Xiaochuan Yang
Filiz Sen
Mark B. Geyer
Inotuzumab ozogamicin as chemotherapy-sparing salvage in a 67-year-old man with primary refractory B-cell acute lymphoblastic leukemia with high-risk genomic features
Leukemia Research Reports
author_facet Xiaochuan Yang
Filiz Sen
Mark B. Geyer
author_sort Xiaochuan Yang
title Inotuzumab ozogamicin as chemotherapy-sparing salvage in a 67-year-old man with primary refractory B-cell acute lymphoblastic leukemia with high-risk genomic features
title_short Inotuzumab ozogamicin as chemotherapy-sparing salvage in a 67-year-old man with primary refractory B-cell acute lymphoblastic leukemia with high-risk genomic features
title_full Inotuzumab ozogamicin as chemotherapy-sparing salvage in a 67-year-old man with primary refractory B-cell acute lymphoblastic leukemia with high-risk genomic features
title_fullStr Inotuzumab ozogamicin as chemotherapy-sparing salvage in a 67-year-old man with primary refractory B-cell acute lymphoblastic leukemia with high-risk genomic features
title_full_unstemmed Inotuzumab ozogamicin as chemotherapy-sparing salvage in a 67-year-old man with primary refractory B-cell acute lymphoblastic leukemia with high-risk genomic features
title_sort inotuzumab ozogamicin as chemotherapy-sparing salvage in a 67-year-old man with primary refractory b-cell acute lymphoblastic leukemia with high-risk genomic features
publisher Elsevier
series Leukemia Research Reports
issn 2213-0489
publishDate 2019-01-01
description Older adults with acute lymphoblastic leukemia (ALL) continue to have a poor prognosis, in part due to greater chemotherapy-related toxicities. We herein report a 67-year-old man with Philadelphia chromosome (Ph)-negative B-cell ALL, who exhibited refractoriness to 3 different regimens of induction chemotherapy and experienced multiple complications including intracranial bleeding and respiratory failure, who achieved minimal residual disease (MRD)-negative complete response (CR) after a single cycle of inotuzumab ozogamicin (IO). His ALL was characterized by several high-risk mutations, which may have contributed to chemotherapy-refractory disease. Our case supports incorporating IO into front-line induction regimens for older adults with high-risk B-cell ALL. Keywords: Acute lymphoblastic leukemia, Inotuzumab ozogamicin, Older adults, Immunotherapy
url http://www.sciencedirect.com/science/article/pii/S2213048919300494
work_keys_str_mv AT xiaochuanyang inotuzumabozogamicinaschemotherapysparingsalvageina67yearoldmanwithprimaryrefractorybcellacutelymphoblasticleukemiawithhighriskgenomicfeatures
AT filizsen inotuzumabozogamicinaschemotherapysparingsalvageina67yearoldmanwithprimaryrefractorybcellacutelymphoblasticleukemiawithhighriskgenomicfeatures
AT markbgeyer inotuzumabozogamicinaschemotherapysparingsalvageina67yearoldmanwithprimaryrefractorybcellacutelymphoblasticleukemiawithhighriskgenomicfeatures
_version_ 1725992599331799040

Similar Items